George Clinical Rebrands as Emerald Clinical Trials
New name reflects company's growth and vision to help bring certainty and…
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiologys Annual Scientific Session 2025
− New Data Follow Recent U.S. FDA Approval of AMVUTTRA® (vutrisiran) as…
Resolutions from the Annual General Meeting of Novo Nordisk A/S
Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual…
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”)…
HRH The Duke of Edinburgh visits Peterborough boxing charity
Monday 3 March, 2025 HRH The Duke of Edinburgh heard about the…
SYNERGIA MEDICAL ANNOUNCES STRONG RESULTS FOR NAO.VNS FIRST-IN-HUMAN STUDY
Primary safety endpoint met - No serious adverse events reported over 3-monthsRobust…
BioAge Labs to Participate in TD Cowen’s 45th Annual Health Care Conference
February 20, 2025 16:30 ET | Source: BioAge Labs, Inc. RICHMOND, Calif.,…
Comanche Biopharma Awarded Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway (ILAP) Steering Group for CBP-4888, an Investigational siRNA Drug Candidate for the Treatment of sFlt1-mediated Preterm Preeclampsia
January 30, 2025 05:00 ET | Source: Comanche Biopharma ILAP aims to…
Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models
Cayman Islands, January 28, 2025 – Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion”…
With significant clinical results published in the Nature Medicine Journal, InBrain Pharma is about to durably modify the advanced Parkinson’s disease management
A World Premiere in Parkinson’s Disease With significant clinical results published in…